Moderna had earlier posted a loss of $2.52 per share a year earlier, while analysts expected a loss of $3.96 per share.

Emcure Pharmaceuticals and its subsidiary Gennova have resolved all legal disputes with US-based HDT Bio Corp. The parties have entered int...

Sanofi, one of the top global vaccine makers, has stated that the current mRNA technology used in COVID-19 vaccines is not effective agains...

The mRNA-based vaccine was developed by Gennova Biopharmaceuticals using the indigenous platform technology, and supported under the Missio...

Decades before Covid vaccines, scientists had been working on messenger ribonucleic acid (mRNA) vaccines targeting cancer.

The Florida Department of Health (Department) conducted an analysis through a self-controlled case series, which is a technique originally ...

The Subject Expert Committee recommended the authorisation in a meeting held on Friday. The vaccine is developed by Pune-based Gennova Biop...

About 70 lakh doses of the vaccine have already been cleared by the government’s nodal Central Drug Laboratory (CDL) at Kasauli and it is e...

Gennova had in April submitted interim data on India's first indigenously developed mRNA Covid-19 vaccine to the Central Drug Standard Cont...

WHO along with its partners will work with the Indian government and BE to develop a roadmap and put in place the necessary training and su...

Gennova Biopharmaceuticals, a subsidiary of Pune-based drugmaker Emcure Pharmaceuticals, is developing a Covid-19 vaccine on its mRNA platf...

The company had submitted the interim Phase-1 clinical trial data to CDSCO, where it tested for safety and immunogenicity.

The study, published in the journal JAMA Pediatrics, offers the first direct data of vaccine safety during breastfeeding and could allay co...

The new technology was not only lightning fast but also incredibly effective - mRNA Covid vaccines from both Moderna and Pfizer hit the bul...

Mumbai-based VAV Lifesciences is the only domestic firm in the COVID-19 vaccine supply chain with this crucial ingredient. It can thus can ...

The DBT said it has approved additional funding towards clinical studies of India's first of its kind' mRNA-based COVID-19 vaccine, HGCO19,...

The trial results are likely to come in by March 2021, Sanjay Singh, CEO of Pune-based Gennova, told ET. There is a possibility that India ...